In June 2025, Nature Medicine published results from the first Phase IIa trial of a drug whose target and molecule were both identified using AI. Rentosertib showed safety comparable to placebo in 71 IPF patients, with exploratory efficacy signals warranting further study. The milestone sits within broader AI adoption across pharma: FDA reviewed over 500 AI-related submissions between 2016 and 2023, and clinical trial AI publications grew 444% from 2019 to 2024. Evidence strength varies by application. AlphaFold's protein structure prediction earned a 2024 Nobel Prize and has three million users. For trial operations, aggregated studies report AI patient recruitment tools improved enrollment rates by 65%, predictive models achieved 85% accuracy in outcome forecasting, and digital biomarkers reached 90% sensitivity for adverse event detection. However, AI has not yet improved pharma's roughly 90% clinical failure rate, and trial duration remains constrained by biology and enrollment logistics. In January 2025, FDA issued draft guidance on AI use in regulatory submissions, the agency's first framework for evaluating AI-generated data in drug applications.
AI in Pharma R&D: What the Evidence Actually Shows for…
AI Clinical ResearchAI drug discoveryFDA AI guidance
AI in Pharma R&D: What the Evidence Actually Shows for Clinical Trials
From the first AI-assisted Phase IIa result to enrollment gains and FDA guidance, here's where the data is strong and where it's still emerging.
FDA AI Submissions
Reviewed 2016 to 2023500+
Clinical Trial AI Pubs
Growth 2019 to 2024444%
Enrollment Rate Gain
AI recruitment tools65%
Discovery Timeline Cut
Early-stage compression30 to 40%
Key Takeaway
AI is compressing early discovery timelines by 30 to 40% and showing enrollment gains in trials, but clinical attrition rates remain unchanged and regulatory frameworks are still in draft form.